Document is current

Article History

Received: 31 July 2025

Revised: 20 January 2026

Accepted: 6 February 2026

First Online: 2 March 2026

Competing interests

: KC declares consulting fees with patient advisory boards of Novo Nordisk and Boehringer Ingelheim and consulting fees with Eli Lilly, Liva Healthcare and Boston Scientific, and a paid role for Obesity UK. There are no other specific financial declarations of interest by all other co-authors.

: This study involved a consensus process with expert participants who contributed in a professional capacity. Formal ethical approval was not required in accordance with national legislation and institutional guidelines, following discussion with the University of Manchester Research Ethics Committee, due to the voluntary nature of expert participation, professionals working with their domain of expertise, anonymisation of data and the consenting process. All participants provided informed consent to participate in the study and were informed of the study aims, methodology, and their right to withdraw at any time. Study methodology was circulated prior to invitation and participation, along with information on data management and anonymisation. Prior to each in-person meeting, consent was taken from participants prior to commencement, and each Delphi form took consent from the participant for the research team to use anonymised data for analysis and future publication. Responses were anonymised to ensure confidentiality.